BiotechTube

Posaconazole + Voriconazole + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fungal Infections

Conditions

Fungal Infections, Invasive Pulmonary Aspergillosis

Trial Timeline

Sep 25, 2013 → Sep 10, 2019

NCT ID
NCT01782131

About Posaconazole + Voriconazole + Placebo

Posaconazole + Voriconazole + Placebo is a phase 3 stage product being developed by Merck for Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01782131. Target conditions include Fungal Infections, Invasive Pulmonary Aspergillosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01782131Phase 3Completed

Competing Products

20 competing products in Fungal Infections

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
41
MicafunginAstellas PharmaPhase 1
33
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPre-clinical
23
FluconazoleAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
caspofungin acetate + Comparator: Micafungin sodiumMerckPhase 3
77
caspofungin acetateMerckPhase 3
77
PosaconazoleMerckPhase 1
33
PosaconazoleMerckApproved
85
Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kgMerckPhase 2
52
Posaconazole oral suspension 40 mg/mLMerckPre-clinical
23
Posaconazole 12 mg/kg/day BID + Posaconazole 18 mg/kg/day BID + Posaconazole 18 mg/kg/day TID + Posaconazole 12 mg/kg/day TIDMerckPhase 1
33
caspofungin acetateMerckPhase 2
52
PosaconazoleMerckPhase 1
33

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85